Holen Sie sich die Stockscreener-App
1,122.50
0.61%
-6.85
Handel nachbörslich:
1121.90
-0.60
-0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,129.35
Offen:
$1138.82
24-Stunden-Volumen:
2.26M
Relative Volume:
0.71
Marktkapitalisierung:
$1.00T
Einnahmen:
$72.25B
Nettoeinkommen (Verlust:
$25.28B
KGV:
40.41
EPS:
27.781
Netto-Cashflow:
$10.37B
1W Leistung:
-1.94%
1M Leistung:
+11.70%
6M Leistung:
+6.47%
1J Leistung:
+39.00%
1-Tages-Spanne:
$1,115.50
$1,146.68
1-Wochen-Bereich:
$1,112.01
$1,170.12
52-Wochen-Spanne:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,122.50 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
235.18 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
222.47 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.93 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.17 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Eli Lilly Broadens Oncology Story With Jaypirca CLL Win And JAK2 Advance - simplywall.st
Lilly bet $2.3B on a Cambridge biotech and its first clinical trial just showed why - MassLive
GLP-1s, Eli Lilly to upgrade Alabama economy - The Business Journals
Early trial data points to Eli Lilly's AJ1-11095 in myelofibrosis - AD HOC NEWS
Why Eli Lilly's Oral Medicine Is Turning Heads? - Kalkine Media
Lilly Backs Abridge to Bring Ambient AI Into Clinical Trial Recruitment - AIM Media House
Eli Lilly Eyes Label Expansion For Leukemia Drug - Benzinga
Lilly Sues Cipla to Block Copy of Breast Cancer Drug Verzenio - Bloomberg Law News
BMO reiterates Outperform on Eli Lilly stock, cites JAK2i data - Investing.com
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Is LLY Overvalued? DCF Says Worth $762 - GuruFocus
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside - Yahoo Finance
Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment - GuruFocus
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Jayp - GuruFocus
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow - AOL.com
Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs Trade Ideas — BCBA:LLY.CI - TradingView
Eli Lilly & Co. Stock (US5324571083): Weekly technical picture in focus - AD HOC NEWS
Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - Investing News Network
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - investor.lilly.com
Eli Lilly & Co. Stock (US5324571083): Novo Nordisk peer check keeps obesity drug leader in focus - AD HOC NEWS
Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds? - Insider Monkey
Lilly trial drug cuts spleen size, symptoms in myelofibrosis - Stock Titan
Jim Cramer Wasn’t Selling Eli Lilly (LLY) - Insider Monkey
Abridge Secures Strategic Investment From Eli Lilly, Expands AI Platform Into Payer and Research Workflows - Digital Health News
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance Australia
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Is Eli Lilly's Growth Story Still Gaining Strength? - Kalkine Media
Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth - Yahoo Finance
The Catch Hiding In Eli Lilly Stock’s Growth Story - Trefis
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About - The Globe and Mail
Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance - Insider Monkey
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy - Yahoo Finance
Prometheus raises $12 billion in capital for artificial engineers - statnews.com
Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline - Insider Monkey
Eli Lilly and Company $LLY is Xponance LLC's 10th Largest Position - MarketBeat
American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Eli Lilly donates $50,000 to Kenosha YMCA for teen services - Kenosha News
Polen Capital Management LLC Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Kovack Advisors Inc. Purchases 3,506 Shares of Eli Lilly and Company $LLY - MarketBeat
IFM Investors Pty Ltd Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Position Boosted by Parnassus Investments LLC - MarketBeat
Nuveen LLC Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
The Catch Hiding In Eli Lilly Stock's Growth Story - Trefis
Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies - Insider Monkey
Eli Lilly Stock Outlook 2026: The Retatrutide Upgrade Cycle - EBC Financial Group
Insider Sell: Ilya Yuffa Sells 2,500 Shares of Eli Lilly and Co (LLY) - GuruFocus
Eli Lilly and Company (NYSE:LLY) Shares Up 2.2%What's Next? - MarketBeat
Eli Lilly Insider Sold Shares Worth $2,876,925, According to a Recent SEC Filing - Moomoo
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.20%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):